Skip to content

Quantum Biopharma Ltd.

QNTM · XNAS

CIK 1771885fmd_0VHC93404JC10M6V86CZQC7T2NManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2018 to Dec 31, 2025, 16 periods

Income Statement · Annual · Millions · USD
Line itemFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Research and development0867463
Selling, general and administrative–––15999
Operating income(22)(31)(34)(27)(24)(16)(15)
Interest expense0000000
Net income from continuing operations(34)(28)(34)(27)(18)(15)(27)
Net income(39)(32)(35)(24)–––
Quantum Biopharma Ltd. (QNTM) financial statements · FinancialMD